Healthcare Services

One of the Major Drivers of the Neuroblastoma Market Is the Rising Childhood Cancer Incidence Driving Growth In The Market

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Neuroblastoma Market Over The Period 2026–2030?

The neuroblastoma market size has shown substantial growth in recent years. It is anticipated to expand from $3.14 billion in 2025 to $3.32 billion in 2026, registering a compound annual growth rate (CAGR) of 5.8%. The historical growth can be attributed to factors such as increased prevalence of pediatric neuroblastoma cases, early adoption of chemotherapy treatments, development of immunotherapy vaccines, growth in clinical diagnosis capabilities, and rising awareness of childhood cancer symptoms.

The neuroblastoma market size is projected to experience substantial growth over the coming years, with an anticipated rise to $4.12 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. This expansion during the forecast period is primarily driven by the broadening of targeted therapy research, increased investment in cell therapy products, greater integration of precision oncology methods, the creation of novel pediatric immunotherapy solutions, and advancements in diagnostic imaging for earlier detection. Significant trends observed in this period encompass the rising uptake of immunotherapy vaccines for pediatric cancer, an increase in the utilization of targeted oral chemotherapy tablets, the escalating development of monoclonal antibody treatments, the expansion of cell therapy and regenerative oncology approaches, and an enhanced emphasis on early diagnosis and symptom management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp

Which Major Factors Are Driving The Expansion Of The Neuroblastoma Market?

The rising occurrence of childhood cancer is projected to stimulate the expansion of the neuroblastoma market going forward. Childhood cancer refers to a range of malignancies primarily affecting children and adolescents, often targeting organs such as the brain, blood, and bones, thus requiring specialized therapeutic approaches. The increase in childhood cancer cases is attributed to elements like improved diagnostic techniques, greater awareness, environmental exposures, genetic predispositions, and advancements in medical research. Neuroblastoma treatment delivers targeted therapies for pediatric cancer, facilitating early and effective intervention that reduces the chance of recurrence and enhances outcomes for young patients. For instance, in May 2024, the American Cancer Society, a US-based professional organization company, indicated that approximately 9,620 children under the age of 15 in the United States are forecast to be diagnosed with cancer in 2024, an increase from 5,290 cases in 2023. Therefore, the growing incidence of childhood cancer is propelling the growth of the neuroblastoma market.

How Is The Neuroblastoma Market Divided Into Its Major Segments?

The neuroblastoma market covered in this report is segmented –

1) By Product Type: Tablets, Vaccines, Other Product Types

2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types

3) By Distribution Channel: Online, Offline

4) By End-User: Hospitals, Clinics

Subsegments:

1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets

2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines

3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products

What Trends Are Affecting The Expansion Of The Neuroblastoma Market?

Major companies in the neuroblastoma market are increasingly focused on developing advanced therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to target and treat cancer cells with greater effectiveness and safety. A humanized anti-GD2 monoclonal antibody is specifically engineered to target the GD2 molecule on cancer cells, integrating human components to reduce immune rejection. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. This antibody is intended for the treatment of newly diagnosed high-risk neuroblastoma, an uncommon and aggressive childhood cancer. Under the terms of this agreement, Renaissance has secured exclusive rights for the development, manufacturing, and commercialization of Hu14.18 across key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

Who Are The Prominent Organizations Shaping The Neuroblastoma Market?

Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

Read the full neuroblastoma market report here:

https://www.thebusinessresearchcompany.com/report/neuroblastoma-global-market-report

Which Region Currently Holds The Largest Share Of The Neuroblastoma Market?

North America was the largest region in the neuroblastoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neuroblastoma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20901&type=smp

Browse Through More Reports Similar to the Global Neuroblastoma Market 2026, By The Business Research Company

Fibromyalgia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Muscle Pain Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Migraine Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795